汇宇制药10月9日获融资买入1062.32万元，融资余额2.13亿元

Core Insights - On October 9, Huayu Pharmaceutical experienced a decline of 0.61% with a trading volume of 74.55 million yuan [1] - The company reported a financing buy-in of 10.62 million yuan and a net financing buy of 2.07 million yuan on the same day [1] - As of October 9, the total balance of margin trading for Huayu Pharmaceutical was 213 million yuan, representing 2.90% of its circulating market value [1] Financing Summary - On October 9, Huayu Pharmaceutical had a financing buy-in of 10.62 million yuan, with a current financing balance of 213 million yuan, which is above the 80th percentile of the past year [1] - The company had no short selling activity on October 9, with a short selling balance of 0.00 yuan, indicating a high level of short selling availability [1] Company Performance - As of June 30, Huayu Pharmaceutical had 16,300 shareholders, a decrease of 11.81% from the previous period, while the average circulating shares per person increased by 25.85% to 21,131 shares [2] - For the first half of 2025, the company reported a revenue of 453 million yuan, a year-on-year decrease of 14.86%, and a net profit attributable to shareholders of -80.72 million yuan, a significant decline of 223.78% [2] - Since its A-share listing, Huayu Pharmaceutical has distributed a total of 474 million yuan in dividends, with 385 million yuan distributed over the past three years [2]